Cellular and Molecular Life Sciences

, Volume 74, Issue 16, pp 2959–2977 | Cite as

Mechanisms and consequences of intestinal dysbiosis

  • G. Adrienne Weiss
  • Thierry HennetEmail author


The composition of the gut microbiota is in constant flow under the influence of factors such as the diet, ingested drugs, the intestinal mucosa, the immune system, and the microbiota itself. Natural variations in the gut microbiota can deteriorate to a state of dysbiosis when stress conditions rapidly decrease microbial diversity and promote the expansion of specific bacterial taxa. The mechanisms underlying intestinal dysbiosis often remain unclear given that combinations of natural variations and stress factors mediate cascades of destabilizing events. Oxidative stress, bacteriophages induction and the secretion of bacterial toxins can trigger rapid shifts among intestinal microbial groups thereby yielding dysbiosis. A multitude of diseases including inflammatory bowel diseases but also metabolic disorders such as obesity and diabetes type II are associated with intestinal dysbiosis. The characterization of the changes leading to intestinal dysbiosis and the identification of the microbial taxa contributing to pathological effects are essential prerequisites to better understand the impact of the microbiota on health and disease.


Bacteria Cytokine Mucin Oxidative stress Bacteriophage Bacteriocins Necrotizing enterocolitis Cancer 



This work is funded by the Swiss National Science Foundation Grant CRSII3_154488/1.


  1. 1.
    Sonnenburg JL, Backhed F (2016) Diet-microbiota interactions as moderators of human metabolism. Nature 535(7610):56–64PubMedCrossRefGoogle Scholar
  2. 2.
    LeBlanc JG et al (2013) Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol 24(2):160–168PubMedCrossRefGoogle Scholar
  3. 3.
    Honda K, Littman DR (2016) The microbiota in adaptive immune homeostasis and disease. Nature 535(7610):75–84PubMedCrossRefGoogle Scholar
  4. 4.
    Thaiss CA et al (2016) The microbiome and innate immunity. Nature 535(7610):65–74PubMedCrossRefGoogle Scholar
  5. 5.
    Mayer EA, Tillisch K, Gupta A (2015) Gut/brain axis and the microbiota. J Clin Invest 125(3):926–938PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Zitvogel L et al (2015) Cancer and the gut microbiota: an unexpected link. Sci Transl Med 7(271):271ps1PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Arumugam M et al (2011) Enterotypes of the human gut microbiome. Nature 473(7346):174–180PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Walker AW et al (2011) High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol 11:7PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Lupp C et al (2007) Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2(2):119–129PubMedCrossRefGoogle Scholar
  10. 10.
    Wlodarska M, Kostic AD, Xavier RJ (2015) An integrative view of microbiome–host interactions in inflammatory bowel diseases. Cell Host Microbe 17(5):577–591PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Gerard P (2016) Gut microbiota and obesity. Cell Mol Life Sci 73(1):147–162PubMedCrossRefGoogle Scholar
  12. 12.
    Knip M, Siljander H (2016) The role of the intestinal microbiota in type 1 diabetes mellitus. Nat Rev Endocrinol 12(3):154–167PubMedCrossRefGoogle Scholar
  13. 13.
    Tremlett H et al (2017) The gut microbiome in human neurological disease: a review. Ann Neurol 81(3):369–382PubMedCrossRefGoogle Scholar
  14. 14.
    Neu J, Walker WA (2011) Necrotizing enterocolitis. N Engl J Med 364(3):255–264PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Schwabe RF, Jobin C (2013) The microbiome and cancer. Nat Rev Cancer 13(11):800–812PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Seekatz AM, Young VB (2014) Clostridium difficile and the microbiota. J Clin Invest 124(10):4182–4189PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Cox, MJ, Cookson WO, Moffatt MF (2013) Sequencing the human microbiome in health and disease. Hum Mol Genet 22(R1):R88–R94PubMedCrossRefGoogle Scholar
  18. 18.
    Turnbaugh PJ et al (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444(7122):1027–1031PubMedCrossRefGoogle Scholar
  19. 19.
    Gregory JC et al (2015) Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem 290(9):5647–5660PubMedCrossRefGoogle Scholar
  20. 20.
    Rakoff-Nahoum S, Foster KR, Comstock LE (2016) The evolution of cooperation within the gut microbiota. Nature 533(7602):255–259PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Chow J, Tang H, Mazmanian SK (2011) Pathobionts of the gastrointestinal microbiota and inflammatory disease. Curr Opin Immunol 23(4):473–480PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Tenaillon O et al (2010) The population genetics of commensal Escherichia coli. Nat Rev Microbiol 8(3):207–217PubMedCrossRefGoogle Scholar
  23. 23.
    Stecher B et al (2007) Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. PLoS Biol 5(10):2177–2189PubMedCrossRefGoogle Scholar
  24. 24.
    Chevalier C et al (2015) Gut microbiota orchestrates energy homeostasis during cold. Cell 163(6):1360–1374PubMedCrossRefGoogle Scholar
  25. 25.
    Li L, Zhao X (2015) Comparative analyses of fecal microbiota in Tibetan and Chinese Han living at low or high altitude by barcoded 454 pyrosequencing. Sci Rep 5:14682PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Ritchie LE et al (2015) Space environmental factor impacts upon murine colon microbiota and mucosal homeostasis. PLoS One 10(6):e0125792PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Scott KP et al (2013) The influence of diet on the gut microbiota. Pharmacol Res 69(1):52–60PubMedCrossRefGoogle Scholar
  28. 28.
    Demehri FR, Barrett M, Teitelbaum DH (2015) Changes to the intestinal microbiome with parenteral nutrition: review of a murine model and potential clinical implications. Nutr Clin Pract 30(6):798–806PubMedCrossRefGoogle Scholar
  29. 29.
    Le Chatelier E et al (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500(7464):541–546PubMedCrossRefGoogle Scholar
  30. 30.
    Ley RE et al (2005) Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 102(31):11070–11075PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Ley RE et al (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444(7122):1022–1023PubMedCrossRefGoogle Scholar
  32. 32.
    Kasai C et al (2015) Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing. BMC Gastroenterol 15:100PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Caricilli AM et al (2011) Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. PLoS Biol 9(12):e1001212PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Cani PD et al (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56(7):1761–1772PubMedCrossRefGoogle Scholar
  35. 35.
    Festi D et al (2014) Gut microbiota and metabolic syndrome. World J Gastroenterol 20(43):16079–16094PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Martinez-Medina M et al (2014) Western diet induces dysbiosis with increased E. coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut 63(1):116–124PubMedCrossRefGoogle Scholar
  37. 37.
    Wu GD et al (2011) Linking long-term dietary patterns with gut microbial enterotypes. Science 334(6052):105–108PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Shankar V et al (2017) Differences in gut metabolites and microbial composition and functions between Egyptian and U.S. children are consistent with their diets. mSystems 2(1)Google Scholar
  39. 39.
    Russell WR et al (2011) High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. Am J Clin Nutr 93(5):1062–1072PubMedCrossRefGoogle Scholar
  40. 40.
    Liu X et al (2014) High-protein diet modifies colonic microbiota and luminal environment but not colonocyte metabolism in the rat model: the increased luminal bulk connection. Am J Physiol Gastrointest Liver Physiol 307(4):G459–G470PubMedCrossRefGoogle Scholar
  41. 41.
    Magee EA et al (2000) Contribution of dietary protein to sulfide production in the large intestine: an in vitro and a controlled feeding study in humans. Am J Clin Nutr 72(6):1488–1494PubMedGoogle Scholar
  42. 42.
    Alemany M (2012) The problem of nitrogen disposal in the obese. Nutr Res Rev 25(1):18–28PubMedCrossRefGoogle Scholar
  43. 43.
    Zahedi Asl S, Ghasemi A, Azizi F (2008) Serum nitric oxide metabolites in subjects with metabolic syndrome. Clin Biochem 41(16–17):1342–1347PubMedCrossRefGoogle Scholar
  44. 44.
    Dykhuizen RS et al (1996) Antimicrobial effect of acidified nitrite on gut pathogens: importance of dietary nitrate in host defense. Antimicrob Agents Chemother 40(6):1422–1425PubMedPubMedCentralGoogle Scholar
  45. 45.
    Zhang C et al (2012) Structural resilience of the gut microbiota in adult mice under high-fat dietary perturbations. ISME J 6(10):1848–1857PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Caesar R et al (2015) Crosstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling. Cell Metab 22(4):658–668PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Bell DS (2015) Changes seen in gut bacteria content and distribution with obesity: causation or association? Postgrad Med 127(8):863–868PubMedCrossRefGoogle Scholar
  48. 48.
    Islam KB et al (2011) Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 141(5):1773–1781PubMedCrossRefGoogle Scholar
  49. 49.
    Murakami Y, Tanabe S, Suzuki T (2016) High-fat diet-induced intestinal hyperpermeability is associated with increased bile acids in the large intestine of mice. J Food Sci 81(1):H216–H222PubMedCrossRefGoogle Scholar
  50. 50.
    Thomas C et al (2008) Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7(8):678–693PubMedCrossRefGoogle Scholar
  51. 51.
    Thomas C, Auwerx J, Schoonjans K (2008) Bile acids and the membrane bile acid receptor TGR5-connecting nutrition and metabolism. Thyroid 18(2):167–174PubMedCrossRefGoogle Scholar
  52. 52.
    Watanabe M et al (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439(7075):484–489PubMedCrossRefGoogle Scholar
  53. 53.
    Fiorucci S, Distrutti E (2015) Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders. Trends Mol Med 21(11):702–714PubMedCrossRefGoogle Scholar
  54. 54.
    De Filippo C et al (2010) Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 107(33):14691–14696PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    DiBaise JK et al (2008) Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 83(4):460–469PubMedCrossRefGoogle Scholar
  56. 56.
    Backhed F et al (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 101(44):15718–15723PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Sanders FW, Griffin JL (2016) De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc 91(2):452–468PubMedCrossRefGoogle Scholar
  58. 58.
    Guarner F, Malagelada JR (2003) Gut flora in health and disease. Lancet 361(9356):512–519PubMedCrossRefGoogle Scholar
  59. 59.
    Arslan N (2014) Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol 20(44):16452–16463PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Le Poul E et al (2003) Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 278(28):25481–25489PubMedCrossRefGoogle Scholar
  61. 61.
    Brown AJ et al (2003) The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 278(13):11312–11319PubMedCrossRefGoogle Scholar
  62. 62.
    Ang Z, Ding JL (2016) GPR41 and GPR43 in obesity and inflammation—protective or causative? Front Immunol 7:28PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Zaibi MS et al (2010) Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett 584(11):2381–2386PubMedCrossRefGoogle Scholar
  64. 64.
    Xiong Y et al (2004) Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc Natl Acad Sci USA 101(4):1045–1050PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Brandsma E et al (2015) The immunity-diet-microbiota axis in the development of metabolic syndrome. Curr Opin Lipidol 26(2):73–81PubMedCrossRefGoogle Scholar
  66. 66.
    Cummings JH et al (1987) Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28(10):1221–1227PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Macfarlane S, Macfarlane GT (2003) Regulation of short-chain fatty acid production. Proc Nutr Soc 62(1):67–72PubMedCrossRefGoogle Scholar
  68. 68.
    Walker AW et al (2011) Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J 5(2):220–230PubMedCrossRefGoogle Scholar
  69. 69.
    Cani PD et al (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58(8):1091–1103PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Everard A et al (2011) Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60(11):2775–2786PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Parnell JA, Reimer RA (2012) Prebiotic fibres dose-dependently increase satiety hormones and alter Bacteroidetes and Firmicutes in lean and obese JCR:LA-cp rats. Br J Nutr 107(4):601–613PubMedCrossRefGoogle Scholar
  72. 72.
    Backhed F et al (2007) Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 104(3):979–984PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Aronsson L et al (2010) Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). PLoS One 5(9)Google Scholar
  74. 74.
    Cani PD, Everard A (2014) Akkermansia muciniphila: a novel target controlling obesity, type 2 diabetes and inflammation? Med Sci (Paris) 30(2):125–127CrossRefGoogle Scholar
  75. 75.
    Everard A et al (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 110(22):9066–9071PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Malik A et al (2016) IL-33 regulates the IgA-microbiota axis to restrain IL-1alpha-dependent colitis and tumorigenesis. J Clin Invest 126(12):4469–4481PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Kang CS et al (2013) Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis. PLoS One 8(10):e76520PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Gilbert HJ (2010) The biochemistry and structural biology of plant cell wall deconstruction. Plant Physiol 153(2):444–455PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Fabich AJ et al (2008) Comparison of carbon nutrition for pathogenic and commensal Escherichia coli strains in the mouse intestine. Infect Immun 76(3):1143–1152PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Pacheco AR et al (2012) Fucose sensing regulates bacterial intestinal colonization. Nature 492(7427):113–117PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Pickard JM et al (2014) Rapid fucosylation of intestinal epithelium sustains host-commensal symbiosis in sickness. Nature 514(7524):638–641PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Vimr ER et al (2004) Diversity of microbial sialic acid metabolism. Microbiol Mol Biol Rev 68(1):132–153PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Marcobal A et al (2011) Bacteroides in the infant gut consume milk oligosaccharides via mucus-utilization pathways. Cell Host Microbe 10(5):507–514PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Ng KM et al (2013) Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 502(7469):96–99PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Huang YL et al (2015) Sialic acid catabolism drives intestinal inflammation and microbial dysbiosis in mice. Nat Commun 6:8141. doi: 10.1038/ncomms9141 PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Rogers MA, Aronoff DM (2016) The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect 178(2):e1–e9Google Scholar
  87. 87.
    Freedberg DE et al (2015) Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 149(4):883–885PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Tsai CF et al (2017) Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study. Gastroenterology 152(1):134–141PubMedCrossRefGoogle Scholar
  89. 89.
    Forslund K et al (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528(7581):262–266PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Korpela K et al (2016) Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nat Commun 7:10410PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Dethlefsen L, Relman DA (2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 108 Suppl 1:4554–4561PubMedCrossRefGoogle Scholar
  92. 92.
    Furuya-Kanamori L et al (2015) Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 36(2):132–141PubMedCrossRefGoogle Scholar
  93. 93.
    Galdston I (1944) Eubiotic medicine. Science 100(2587):76PubMedCrossRefGoogle Scholar
  94. 94.
    Guslandi M (2011) Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol 17(42):4643–4646PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Pimentel M et al (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364(1):22–32PubMedCrossRefGoogle Scholar
  96. 96.
    Swanson HI (2015) Drug metabolism by the host and gut microbiota: a partnership or rivalry? Drug Metab Dispos 43(10):1499–1504PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Aura AM et al (2011) Drug metabolome of the simvastatin formed by human intestinal microbiota in vitro. Mol Biosyst 7(2):437–446PubMedCrossRefGoogle Scholar
  98. 98.
    Yadav V et al (2013) Colonic bacterial metabolism of corticosteroids. Int J Pharm 457(1):268–274PubMedCrossRefGoogle Scholar
  99. 99.
    Wallace BD et al (2010) Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330(6005):831–835PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Lim YJ, Yang CH (2012) Non-steroidal anti-inflammatory drug-induced enteropathy. Clin Endosc 45(2):138–144PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Robbe C et al (2003) Evidence of regio-specific glycosylation in human intestinal mucins: presence of an acidic gradient along the intestinal tract. J Biol Chem 278(47):46337–46348PubMedCrossRefGoogle Scholar
  102. 102.
    Corfield AP (2015) Mucins: a biologically relevant glycan barrier in mucosal protection. Biochim Biophys Acta 1850(1):236–252PubMedCrossRefGoogle Scholar
  103. 103.
    Ahn DH et al (2005) TNF-alpha activates MUC2 transcription via NF-kappaB but inhibits via JNK activation. Cell Physiol Biochem 15(1–4):29–40PubMedCrossRefGoogle Scholar
  104. 104.
    Hokari R et al (2005) Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1. Am J Physiol Gastrointest Liver Physiol 289(5):G949–G959PubMedCrossRefGoogle Scholar
  105. 105.
    Larsson JM et al (2011) Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. Inflamm Bowel Dis 17(11):2299–2307PubMedCrossRefGoogle Scholar
  106. 106.
    Goto Y et al (2014) Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science 345(6202):1254009PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Png CW et al (2010) Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 105(11):2420–2428PubMedCrossRefGoogle Scholar
  108. 108.
    Sela DA et al (2008) The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization within the infant microbiome. Proc Natl Acad Sci USA 105(48):18964–18969PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Derrien M et al (2004) Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 54(Pt 5):1469–1476PubMedCrossRefGoogle Scholar
  110. 110.
    Martens EC, Chiang HC, Gordon JI (2008) Mucosal glycan foraging enhances fitness and transmission of a saccharolytic human gut bacterial symbiont. Cell Host Microbe 4(5):447–457PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Etzold S, Juge N (2014) Structural insights into bacterial recognition of intestinal mucins. Curr Opin Struct Biol 28C:23–31CrossRefGoogle Scholar
  112. 112.
    Mahdavi J et al (2014) A novel O-linked glycan modulates Campylobacter jejuni major outer membrane protein-mediated adhesion to human histo-blood group antigens and chicken colonization. Open Biol 4:130202PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Ruiz-Palacios GM et al (2003) Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem 278(16):14112–14120PubMedCrossRefGoogle Scholar
  114. 114.
    Kyogashima M, Ginsburg V, Krivan HC (1989) Escherichia coli K99 binds to N-glycolylsialoparagloboside and N-glycolyl-GM3 found in piglet small intestine. Arch Biochem Biophys 270(1):391–397PubMedCrossRefGoogle Scholar
  115. 115.
    Byres E et al (2008) Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin. Nature 456(7222):648–652PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Tangvoranuntakul P et al (2003) Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA 100(21):12045–12050PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Barr JJ et al (2013) Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc Natl Acad Sci USA 110(26):10771–10776PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    McGovern DP et al (2010) Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn’s disease. Hum Mol Genet 19(17):3468–3476PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    Johansson ME et al (2015) Normalization of host intestinal mucus layers requires long-term microbial colonization. Cell Host Microbe 18(5):582–592PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Hooper LV, Macpherson AJ (2010) Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 10(3):159–169PubMedCrossRefGoogle Scholar
  121. 121.
    Suzuki K et al (2004) Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci USA 101(7):1981–1986PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Elinav E et al (2011) NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145(5):745–757PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Wlodarska M et al (2014) NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell 156(5):1045–1059PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Nowarski R et al (2015) Epithelial IL-18 equilibrium controls barrier function in colitis. Cell 163(6):1444–1456PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Gersemann M et al (2009) Differences in goblet cell differentiation between Crohn’s disease and ulcerative colitis. Differentiation 77(1):84–94PubMedCrossRefGoogle Scholar
  126. 126.
    Huber S et al (2012) IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491(7423):259–263PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Zheng Y et al (2008) Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 14(3):282–289PubMedCrossRefGoogle Scholar
  128. 128.
    McSorley SJ et al (2002) Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol 169(7):3914–3919PubMedCrossRefGoogle Scholar
  129. 129.
    McDermott PF et al (2000) High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation. Infect Immun 68(10):5525–5529PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Van Maele L et al (2010) TLR5 signaling stimulates the innate production of IL-17 and IL-22 by CD3(neg)CD127+ immune cells in spleen and mucosa. J Immunol 185(2):1177–1185PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Vijay-Kumar M et al (2010) Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328(5975):228–231PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Vijay-Kumar M et al (2007) Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest 117(12):3909–3921PubMedPubMedCentralGoogle Scholar
  133. 133.
    Carvalho FA et al (2012) Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. Cell Host Microbe 12(2):139–152PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Kobayashi KS et al (2005) Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307(5710):731–734PubMedCrossRefGoogle Scholar
  135. 135.
    Petnicki-Ocwieja T et al (2009) Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci USA 106(37):15813–15818PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Salzman NH et al (2010) Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 11(1):76–83PubMedCrossRefGoogle Scholar
  137. 137.
    Ogura Y et al (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411(6837):603–606PubMedCrossRefGoogle Scholar
  138. 138.
    Wehkamp J et al (2005) Reduced Paneth cell alpha-defensins in ileal Crohn’s disease. Proc Natl Acad Sci USA 102(50):18129–18134PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Davis CP, Savage DC (1974) Habitat, succession, attachment, and morphology of segmented, filamentous microbes indigenous to the murine gastrointestinal tract. Infect Immun 10(4):948–956PubMedPubMedCentralGoogle Scholar
  140. 140.
    Kumar P et al (2016) Intestinal interleukin-17 receptor signaling mediates reciprocal control of the gut microbiota and autoimmune inflammation. Immunity 44(3):659–671PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Gaboriau-Routhiau V et al (2009) The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31(4):677–689PubMedCrossRefGoogle Scholar
  142. 142.
    Sakaguchi S et al (2008) Regulatory T cells and immune tolerance. Cell 133(5):775–787PubMedCrossRefGoogle Scholar
  143. 143.
    Arthur JC et al (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338(6103):120–123PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Wohlgemuth S et al (2009) Reduced microbial diversity and high numbers of one single Escherichia coli strain in the intestine of colitic mice. Environ Microbiol 11(6):1562–1571PubMedCrossRefGoogle Scholar
  145. 145.
    Di Giacinto C et al (2005) Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol 174(6):3237–3246PubMedCrossRefGoogle Scholar
  146. 146.
    Sokol H et al (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105(43):16731–16736PubMedPubMedCentralCrossRefGoogle Scholar
  147. 147.
    Kashiwagi I et al (2015) Smad2 and Smad3 inversely regulate TGF-beta autoinduction in clostridium butyricum-activated dendritic cells. Immunity 43(1):65–79PubMedCrossRefGoogle Scholar
  148. 148.
    Ihara S et al (2016) TGF-beta signaling in dendritic cells governs colonic homeostasis by controlling epithelial differentiation and the luminal microbiota. J Immunol 196(11):4603–4613PubMedCrossRefGoogle Scholar
  149. 149.
    Sato J et al (2014) Gut dysbiosis and detection of “live gut bacteria” in blood of Japanese patients with type 2 diabetes. Diabetes Care 37(8):2343–2350PubMedCrossRefGoogle Scholar
  150. 150.
    Mazmanian SK, Kasper DL (2006) The love-hate relationship between bacterial polysaccharides and the host immune system. Nat Rev Immunol 6(11):849–858PubMedCrossRefGoogle Scholar
  151. 151.
    Ivanov II et al (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139(3):485–498PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Karczewski J et al (2014) The effects of the microbiota on the host immune system. Autoimmunity 47(8):494–504PubMedCrossRefGoogle Scholar
  153. 153.
    Wen L et al (2008) Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455(7216):1109–1113PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Burrows MP et al (2015) Microbiota regulates type 1 diabetes through Toll-like receptors. Proc Natl Acad Sci USA 112(32):9973–9977PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Larsson E et al (2012) Analysis of gut microbial regulation of host gene expression along the length of the gut and regulation of gut microbial ecology through MyD88. Gut 61(8):1124–1131PubMedCrossRefGoogle Scholar
  156. 156.
    Kriegel MA et al (2011) Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc Natl Acad Sci USA 108(28):11548–11553PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    Clarke TB et al (2010) Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 16(2):228–231PubMedPubMedCentralCrossRefGoogle Scholar
  158. 158.
    Ganal SC et al (2012) Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity 37(1):171–186PubMedCrossRefGoogle Scholar
  159. 159.
    Khosravi A et al (2014) Gut microbiota promote hematopoiesis to control bacterial infection. Cell Host Microbe 15(3):374–381PubMedPubMedCentralCrossRefGoogle Scholar
  160. 160.
    Hill DA et al (2012) Commensal bacteria-derived signals regulate basophil hematopoiesis and allergic inflammation. Nat Med 18(4):538–546PubMedPubMedCentralCrossRefGoogle Scholar
  161. 161.
    Zeissig S, Blumberg RS (2014) Life at the beginning: perturbation of the microbiota by antibiotics in early life and its role in health and disease. Nat Immunol 15(4):307–310PubMedCrossRefGoogle Scholar
  162. 162.
    Ng SC et al (2013) Geographical variability and environmental risk factors in inflammatory bowel disease. Gut 62(4):630–649PubMedCrossRefGoogle Scholar
  163. 163.
    Murk W, Risnes KR, Bracken MB (2011) Prenatal or early-life exposure to antibiotics and risk of childhood asthma: a systematic review. Pediatrics 127(6):1125–1138PubMedCrossRefGoogle Scholar
  164. 164.
    Flohr C, Pascoe D, Williams HC (2005) Atopic dermatitis and the ‘hygiene hypothesis’: too clean to be true? Br J Dermatol 152(2):202–216PubMedCrossRefGoogle Scholar
  165. 165.
    Winter SE et al (2010) Gut inflammation provides a respiratory electron acceptor for Salmonella. Nature 467(7314):426–429PubMedPubMedCentralCrossRefGoogle Scholar
  166. 166.
    Scanlan PD, Shanahan F, Marchesi JR (2009) Culture-independent analysis of desulfovibrios in the human distal colon of healthy, colorectal cancer and polypectomized individuals. FEMS Microbiol Ecol 69(2):213–221PubMedCrossRefGoogle Scholar
  167. 167.
    Hensel M et al (1999) The genetic basis of tetrathionate respiration in Salmonella typhimurium. Mol Microbiol 32(2):275–287PubMedCrossRefGoogle Scholar
  168. 168.
    Pryor WA, Squadrito GL (1995) The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol 268(5 Pt 1):L699–L722PubMedGoogle Scholar
  169. 169.
    Winter SE et al (2013) Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science 339(6120):708–711PubMedPubMedCentralCrossRefGoogle Scholar
  170. 170.
    Lopez CA et al (2012) Phage-mediated acquisition of a type III secreted effector protein boosts growth of salmonella by nitrate respiration. MBio 3(3)Google Scholar
  171. 171.
    Manrique P et al (2016) Healthy human gut phageome. Proc Natl Acad Sci USA 113(37):10400–10405PubMedPubMedCentralCrossRefGoogle Scholar
  172. 172.
    Minot S et al (2011) The human gut virome: inter-individual variation and dynamic response to diet. Genome Res 21(10):1616–1625PubMedPubMedCentralCrossRefGoogle Scholar
  173. 173.
    Stern A et al (2012) CRISPR targeting reveals a reservoir of common phages associated with the human gut microbiome. Genome Res 22(10):1985–1994PubMedPubMedCentralCrossRefGoogle Scholar
  174. 174.
    Norman JM et al (2015) Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 160(3):447–460PubMedPubMedCentralCrossRefGoogle Scholar
  175. 175.
    Zhang X et al (2000) Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 181(2):664–670PubMedCrossRefGoogle Scholar
  176. 176.
    Fraser JS, Maxwell KL, Davidson AR (2007) Immunoglobulin-like domains on bacteriophage: weapons of modest damage? Curr Opin Microbiol 10(4):382–387PubMedCrossRefGoogle Scholar
  177. 177.
    Arike L, Hansson GC (2016) The densely O-glycosylated MUC2 mucin protects the intestine and provides food for the commensal bacteria. J Mol Biol 428(16):3221–3229PubMedCrossRefGoogle Scholar
  178. 178.
    Kim YS, Ho SB (2010) Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 12(5):319–330PubMedPubMedCentralCrossRefGoogle Scholar
  179. 179.
    Cotter PD, Hill C, Ross RP (2005) Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 3(10):777–788PubMedCrossRefGoogle Scholar
  180. 180.
    Rebuffat S (2012) Microcins in action: amazing defence strategies of Enterobacteria. Biochem Soc Trans 40(6):1456–1462PubMedCrossRefGoogle Scholar
  181. 181.
    Ghazaryan L et al (2014) The role of stress in colicin regulation. Arch Microbiol 196(11):753–764PubMedCrossRefGoogle Scholar
  182. 182.
    Patzer SI et al (2003) The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN. Microbiology 149(Pt 9):2557–2570PubMedCrossRefGoogle Scholar
  183. 183.
    Sassone-Corsi M et al (2016) Microcins mediate competition among Enterobacteriaceae in the inflamed gut. Nature 540(7632):280–283PubMedPubMedCentralCrossRefGoogle Scholar
  184. 184.
    Losurdo G et al (2015) Escherichia coli Nissle 1917 in Ulcerative colitis treatment: systematic review and meta-analysis. J Gastrointestin Liver Dis 24(4):499–505PubMedGoogle Scholar
  185. 185.
    Scaldaferri F et al (2016) Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update. World J Gastroenterol 22(24):5505–5511PubMedPubMedCentralCrossRefGoogle Scholar
  186. 186.
    Kommineni S et al (2015) Bacteriocin production augments niche competition by enterococci in the mammalian gastrointestinal tract. Nature 526(7575):719–722PubMedPubMedCentralCrossRefGoogle Scholar
  187. 187.
    Gebhart D et al (2015) A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity. MBio 6(2)Google Scholar
  188. 188.
    Xin B et al (2016) Thusin, a novel two-component lantibiotic with potent antimicrobial activity against several gram-positive pathogens. Front Microbiol 7:1115PubMedPubMedCentralCrossRefGoogle Scholar
  189. 189.
    Cammarota G et al (2015) The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol Ther 149:191–212PubMedCrossRefGoogle Scholar
  190. 190.
    Scott FW et al (2017) Where genes meet environment-integrating the role of gut luminal contents, immunity and pancreas in type 1 diabetes. Transl Res 179:183–198PubMedCrossRefGoogle Scholar
  191. 191.
    Losurdo G et al (2016) The interaction between celiac disease and intestinal microbiota. J Clin Gastroenterol 50(Suppl 2):S145–S147PubMedCrossRefGoogle Scholar
  192. 192.
    Tang WH, Hazen SL (2014) The contributory role of gut microbiota in cardiovascular disease. J Clin Invest 124(10):4204–4211PubMedPubMedCentralCrossRefGoogle Scholar
  193. 193.
    Lucas A, Cole TJ (1990) Breast milk and neonatal necrotising enterocolitis. Lancet 336(8730):1519–1523PubMedCrossRefGoogle Scholar
  194. 194.
    Gartner LM et al (2005) Breastfeeding and the use of human milk. Pediatrics 115(2):496–506PubMedCrossRefGoogle Scholar
  195. 195.
    Foster JP, Seth R, Cole MJ (2016) Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth weight neonates. Cochrane Database Syst Rev 4:CD001816PubMedGoogle Scholar
  196. 196.
    Srinivasjois R, Rao S, Patole S (2013) Prebiotic supplementation in preterm neonates: updated systematic review and meta-analysis of randomised controlled trials. Clin Nutr 32(6):958–965PubMedCrossRefGoogle Scholar
  197. 197.
    Costeloe K et al (2016) Bifidobacterium breve BBG-001 in very preterm infants: a randomised controlled phase 3 trial. Lancet 387(10019):649–660PubMedCrossRefGoogle Scholar
  198. 198.
    Kuper H, Adami HO, Trichopoulos D (2000) Infections as a major preventable cause of human cancer. J Intern Med 248(3):171–183PubMedCrossRefGoogle Scholar
  199. 199.
    Irrazabal T et al (2014) The multifaceted role of the intestinal microbiota in colon cancer. Mol Cell 54(2):309–320PubMedCrossRefGoogle Scholar
  200. 200.
    Franco AT et al (2005) Activation of beta-catenin by carcinogenic Helicobacter pylori. Proc Natl Acad Sci USA 102(30):10646–10651PubMedPubMedCentralCrossRefGoogle Scholar
  201. 201.
    Wang F et al (2014) Helicobacter pylori infection and normal colorectal mucosa-adenomatous polyp-adenocarcinoma sequence: a meta-analysis of 27 case–control studies. Colorectal Dis 16(4):246–252PubMedCrossRefGoogle Scholar
  202. 202.
    Hatakeyama M, Higashi H (2005) Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis. Cancer Sci 96(12):835–843PubMedCrossRefGoogle Scholar
  203. 203.
    Gao Z et al (2015) Microbiota disbiosis is associated with colorectal cancer. Front Microbiol 6:20PubMedPubMedCentralGoogle Scholar
  204. 204.
    Ahn J et al (2013) Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 105(24):1907–1911PubMedPubMedCentralCrossRefGoogle Scholar
  205. 205.
    Castellarin M et al (2012) Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22(2):299–306PubMedPubMedCentralCrossRefGoogle Scholar
  206. 206.
    Han YW et al (2005) Identification and characterization of a novel adhesin unique to oral fusobacteria. J Bacteriol 187(15):5330–5340PubMedPubMedCentralCrossRefGoogle Scholar
  207. 207.
    Fardini Y et al (2011) Fusobacterium nucleatum adhesin FadA binds vascular endothelial cadherin and alters endothelial integrity. Mol Microbiol 82(6):1468–1480PubMedPubMedCentralCrossRefGoogle Scholar
  208. 208.
    Rubinstein MR et al (2013) Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 14(2):195–206PubMedPubMedCentralCrossRefGoogle Scholar
  209. 209.
    Rakoff-Nahoum S, Medzhitov R (2007) Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317(5834):124–127PubMedCrossRefGoogle Scholar
  210. 210.
    Salcedo R et al (2010) MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 207(8):1625–1636PubMedPubMedCentralCrossRefGoogle Scholar
  211. 211.
    Hu B et al (2010) Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci USA 107(50):21635–21640PubMedPubMedCentralCrossRefGoogle Scholar
  212. 212.
    Zaki MH et al (2010) IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol 185(8):4912–4920PubMedPubMedCentralCrossRefGoogle Scholar
  213. 213.
    Chen GY et al (2011) A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J Immunol 186(12):7187–7194PubMedPubMedCentralCrossRefGoogle Scholar
  214. 214.
    Saleh M, Trinchieri G (2011) Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol 11(1):9–20PubMedCrossRefGoogle Scholar
  215. 215.
    Fukata M et al (2007) Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133(6):1869–1881PubMedPubMedCentralCrossRefGoogle Scholar
  216. 216.
    Wang EL et al (2010) High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 102(5):908–915PubMedPubMedCentralCrossRefGoogle Scholar
  217. 217.
    Doan HQ et al (2009) Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res 29(7):2473–2478PubMedPubMedCentralGoogle Scholar
  218. 218.
    Fukata M et al (2006) Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 131(3):862–877PubMedPubMedCentralCrossRefGoogle Scholar
  219. 219.
    Fukata M, Abreu MT (2007) TLR4 signalling in the intestine in health and disease. Biochem Soc Trans 35(Pt 6):1473–1478PubMedCrossRefGoogle Scholar
  220. 220.
    Yu LC et al (2012) Host-microbial interactions and regulation of intestinal epithelial barrier function: from physiology to pathology. World J Gastrointest Pathophysiol 3(1):27–43PubMedPubMedCentralCrossRefGoogle Scholar
  221. 221.
    Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4(8):579–591PubMedCrossRefGoogle Scholar
  222. 222.
    Cario E, Podolsky DK (2000) Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 68(12):7010–7017PubMedPubMedCentralCrossRefGoogle Scholar
  223. 223.
    Bernstein CN et al (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91(4):854–862PubMedCrossRefGoogle Scholar
  224. 224.
    Lukas M (2010) Inflammatory bowel disease as a risk factor for colorectal cancer. Dig Dis 28(4–5):619–624PubMedCrossRefGoogle Scholar
  225. 225.
    Uronis JM et al (2009) Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 4(6):e6026PubMedPubMedCentralCrossRefGoogle Scholar
  226. 226.
    Azcarate-Peril MA, Sikes M, Bruno-Barcena JM (2011) The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer? Am J Physiol Gastrointest Liver Physiol 301(3):G401–G424PubMedPubMedCentralCrossRefGoogle Scholar
  227. 227.
    Wu S et al (2003) Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology 124(2):392–400PubMedCrossRefGoogle Scholar
  228. 228.
    Goodwin AC et al (2011) Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc Natl Acad Sci USA 108(37):15354–15359PubMedPubMedCentralCrossRefGoogle Scholar
  229. 229.
    Cuevas-Ramos G et al (2010) Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci USA 107(25):11537–11542PubMedPubMedCentralCrossRefGoogle Scholar
  230. 230.
    Singh N et al (2014) Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40(1):128–139PubMedPubMedCentralCrossRefGoogle Scholar
  231. 231.
    Alasmari F et al (2014) Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis 59(2):216–222PubMedPubMedCentralCrossRefGoogle Scholar
  232. 232.
    Carter GP, Rood JI, Lyras D (2012) The role of toxin A and toxin B in the virulence of Clostridium difficile. Trends Microbiol 20(1):21–29PubMedCrossRefGoogle Scholar
  233. 233.
    Kelly CP et al (1994) Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest 93(3):1257–1265PubMedPubMedCentralCrossRefGoogle Scholar
  234. 234.
    Sorg JA, Sonenshein AL (2008) Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 190(7):2505–2512PubMedPubMedCentralCrossRefGoogle Scholar
  235. 235.
    Wilson KH, Perini F (1988) Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immun 56(10):2610–2614PubMedPubMedCentralGoogle Scholar
  236. 236.
    Theriot CM et al (2014) Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 5:3114PubMedPubMedCentralCrossRefGoogle Scholar
  237. 237.
    Buffie CG et al (2012) Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun 80(1):62–73PubMedPubMedCentralCrossRefGoogle Scholar
  238. 238.
    Lawley TD et al (2012) Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 8(10):e1002995PubMedPubMedCentralCrossRefGoogle Scholar
  239. 239.
    Reeves AE et al (2011) The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2(3):145–158PubMedPubMedCentralCrossRefGoogle Scholar
  240. 240.
    Hopkins MJ, Macfarlane GT (2002) Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol 51(5):448–454PubMedCrossRefGoogle Scholar
  241. 241.
    Rea MC et al (2012) Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol 50(3):867–875PubMedPubMedCentralCrossRefGoogle Scholar
  242. 242.
    van Nood E et al (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368(5):407–415PubMedCrossRefGoogle Scholar
  243. 243.
    Garza DR, Dutilh BE (2015) From cultured to uncultured genome sequences: metagenomics and modeling microbial ecosystems. Cell Mol Life Sci 72(22):4287–4308PubMedPubMedCentralCrossRefGoogle Scholar
  244. 244.
    Thiele I, Palsson BO (2010) A protocol for generating a high-quality genome-scale metabolic reconstruction. Nat Protoc 5(1):93–121PubMedPubMedCentralCrossRefGoogle Scholar
  245. 245.
    Chen J et al (2007) Improving metabolic flux estimation via evolutionary optimization for convex solution space. Bioinformatics 23(9):1115–1123PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing 2017

Authors and Affiliations

  1. 1.Institute of PhysiologyUniversity of ZurichZurichSwitzerland

Personalised recommendations